Local: Los Angeles, CA  (change)

 | 

Join the Topix community today: 

Sign Up

 | 

Sign In

Advertisment

VIVUS News

News on VIVUS continually updated from thousands of sources around the net.

Aug 5, 2008 | BioSpace

VIVUS, Inc. Plans $65M Stock Sale

VIVUS, Inc. , a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it has entered into definitive agreements dated August 5, 2008 with ...

Comment?

Related Topix: Medicine, Corporate / Securities Law, Law, Securities and Exchange Commission, Startups, VIVUS, Biotech, Medical Equipment, Healthcare Industry

Fri Jul 18, 2008

Fool.com

7 Stocks Defying the Doubters

Successful investing requires you to think independently and stick to your convictions.

Comment?

Related Topix: Startups, VIVUS, Biotech, Medicine, Regeneron Pharmaceuticals, Healthcare Industry, Midway Games, Video Games, Software, Medical Equipment, Financial Markets

Thu Jun 26, 2008

San Francisco Business Times

Vivus reports good news from diabetes drug test

Vivus Inc. 's diabetes drug Qnexa did well in a mid-stage clinical trial in obese patients.

Comment?

Related Topix: Medicine, Diabetes, Health, Biotech, Medical Equipment, Healthcare Industry

Thu Jun 19, 2008

TradingMarkets.com

5 Top PowerRatings Stocks Under $15: OPTM, VVUS, AVAN, TWP, VCI

Stocks continued to move lower in the first few hours of trading on Thursday as lower initial jobless claims and declining oil prices failed to inspire buyers.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Medical Equipment

Sun Jun 15, 2008

Business Wire

Public relations, press release distribution, investor relations, SEC filing

Commonwealth Bank of Australia Issue of EUR 5,000,000 Floating Rate Notes due May 2009 Series 3422 Tranche 1 MTN ISSUE NAME.

Comment?

Related Topix: Automakers, Brilliance China Automotive Holdings, Banking, Financial Services, Mountain View, CA, Startups, VIVUS, Biotech, Medicine, Medical Equipment, Healthcare Industry, San Diego Metro

Fri Jun 13, 2008

Med Ad News

VIVUS Announces Presentation of Qnexa Data at the 2008 BIO International Convention

Jun 13, 2008 - VIVUS, Inc a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that, Peter Tam, senior vice president of Product and ...

Comment?

Related Topix: Startups, VIVUS, Biotech, Medicine, Medical Equipment, Healthcare Industry

Fri Jun 06, 2008

Medical News Today

VIVUS Announces The Podium Presentation Of Phase 2 Data For Qnexa In...

Main Category: Diabetes Also Included In: Conferences Article Date: 06 Jun 2008 - 4:00 PDT VIVUS, Inc a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, ...

Comment?

Related Topix: Health, Startups, VIVUS, Medicine, Diabetes, Biotech, Medical Equipment, Healthcare Industry, San Francisco Metro

Sat May 31, 2008

The Biotech Stock Blog

VIVUS Inc. Q1 2008 Earnings Call Transcript

Tim Morris - VP Finance and CFO Leland Wilson - President and CEO Peter Tam - SVP Product & Corporate Development Analysts Corey Kasimov - JPMorgan Ian Sanderson - Cowen and Company Ruthanne Roussel - Robins ...

Comment?

Related Topix: Startups, VIVUS, Biotech, Medicine, Medical Equipment, Healthcare Industry, Healthcare Law

Fri May 30, 2008

San Jose Mercury News

Notable movers

Vivus was down 79 cents, or 10.7 percent, to $6.57. The Mountain View developer of drugs for sexual dysfunction and obesity was cut to "market perform" from "outperform" by Wachovia analysts, who said investors ...

Comment?

Related Topix: Biotech, Medical Equipment, Medicine, Healthcare Industry, Business News

Wed Apr 23, 2008

BioSpace

More...

“Obesity is a major epidemic that significantly contributes to early death due to cardiovascular disease, diabetes, and cancer. Our phase 3 program is designed to evaluate weight loss in these patients and potential benefit on their co-morbidities”

VIVUS, Inc. , a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it has completed enrollment in the final of three phase 3 studies of ... via BioSpace

Comment?

Related Topix: Medicine, Diabetes, Health, Startups, VIVUS, Biotech, Medical Equipment, Healthcare Industry, Healthcare Law, Law, Food and Drug Administration

Mon Apr 21, 2008

Bizjournals

Vivus adds former Osteologix CEO with much merger experience to board

“This experience will be helpful as we look to the future”

San Francisco Business Times - by Steven E.F. Brown Drug company Vivus Inc. , which focuses on treatments for obesity and sexual problems, added Charles Casamento, the former CEO of Osteologix Inc. via Bizjournals

Comment?

Related Topix: Osteologix, Startups, Biotech, Medicine, Medical Equipment, Healthcare Industry, Erectile Dysfunction, Health, VIVUS, SuperGen

Fri Apr 04, 2008

BioSpace

More...

“We are pleased to have entered into this collaboration with Vivus that provides full funding for phase 3 while avoiding significant shareholder dilution.”

VIVUS, Inc. announced today that it has entered into a $30 million funding collaboration with Deerfield Management . via BioSpace

Comment?

Related Topix: Management Network Group Inc The, Consulting, Erectile Dysfunction, Medicine, Health, Startups, VIVUS, Biotech, Medical Equipment, Healthcare Industry

Thu Apr 03, 2008

Fool.com

VIVUS' New Old Drugs

Last week, tiny drugmaker VIVUS said it had completed enrollment for a phase 3 study of its anti-obesity drug Qnexa. via Fool.com

Comment?

Related Topix: Biotech, Medicine, Eli Lilly, Healthcare Industry, Pfizer, Startups, VIVUS, Medical Equipment

Tue Apr 01, 2008

BioSpace

More...

VIVUS, Inc. announced today that it has successfully completed and reached agreement with the U.S. Food and Drug Administration regarding the Special Protocol Assessment for the phase 3 efficacy trials for ... via BioSpace

Comment?

Related Topix: Startups, VIVUS, Food and Drug Administration, Biotech, Medical Equipment, Healthcare Industry

Thu Mar 27, 2008

Med Ad News

VIVUS Completes Enrollment in Phase 3 EQUIP (OB-302) Trial

“We anticipate that the results of the study will be available in the second half of 2009.”

March 27, 2008 - VIVUS, Inc. , a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it has completed enrollment in the first of two ... via Med Ad News

Comment?

Related Topix: Medicine, Startups, VIVUS, Biotech, Medical Equipment, Healthcare Industry

Fri Mar 07, 2008

Ticker

Earnings: Ciena, Vivus and Carrols

Author: 123jump.com Staff 123jump.com Last Update: 4:01 PM EST March 07 2008 Ciena surged 11% after it reported first quarter revenue increase of 38% to $227.4 million and net income increase of 160%. Ciena ... via Ticker

Comment?

Related Topix: Biotech, Medical Equipment, Medicine, Healthcare Industry, CIENA, Telecom

Tue Mar 04, 2008

Business Wire

Public relations, press release distribution, investor relations, SEC filing

MOUNTAIN VIEW, Calif.-- --VIVUS, Inc. , a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced - BOSTON-- --Exclusive new research from ... via Business Wire

Comment?

Related Topix: Mountain View, CA, Startups, VIVUS, Biotech, Medicine, Medical Equipment, Healthcare Industry, Corporate Governance, Los Angeles Metro

Wed Jan 09, 2008

PR-inside.com

VIVUS Initiates Extension Study with Qnexa for Diabetes

Timothy E. Morris, 650-934-5200 Chief Financial Officer or Trout Group Ian Clements , 415-392-3385 or Brian Korb , 646-378-2923 VIVUS, Inc a pharmaceutical company dedicated to the development and ... via PR-inside.com

Comment?

Related Topix: Startups, VIVUS, Biotech, Medicine, Diabetes, Medical Equipment, Health, Healthcare Industry

Business Wire

Public relations, press release distribution, investor relations, SEC filing

BioTime, Inc. announced it has signed a licensing agreement with the Wisconsin Alumni Research Foundation to 173 patents and patent - VIVUS Initiates Extension Study with Qnexa for Diabetes MOUNTAIN VIEW, ... via Business Wire

Comment?

Related Topix: Mountain View, CA, Elixir, Electronic, Marketing, San Francisco Metro, Biotech, Medicine, Medical Equipment, Healthcare Industry

Wed Dec 12, 2007

PR-inside.com

VIVUS Initiates Third Qnexa Phase 3 Trial in Obese Patients

“The initiation of the EQUATE study completes our plans for phase 3 studies of Qnexa. The EQUATE study will evaluate two doses of Qnexa over 6 months and should give us an early look at the outcomes of the larger pivotal phase 3 studies”

Timothy E. Morris, 650-934-5200 Chief Financial Officer or Trout Group Ian Clements , 415-392-3385 Brian Korb , 646-378-2923 VIVUS, Inc. via PR-inside.com

Comment?

Related Topix: Law, Startups, VIVUS, Healthcare Law, Biotech, Medicine, Medical Equipment, Healthcare Industry, Phentermine (generic), Ionamin, Adipex-P, Medication

↑ Back to top

More VIVUS News

Archives

Read more articles in the VIVUS News Archives.

For up to the minute news, check out the VIVUS News Wire.

Want to add VIVUS News headlines to your web site? Get the widget here.

RSS icon mobile icon

VIVUS Photos

VIVUS News Editors

RoboBlogger

I edit this news page on Topix when no humans are available to help.

People just like you make VIVUS News on Topix better every day. If you're interested in becoming an editor, apply today!

Edits History | Editor Blog

VIVUS Poll

created by: Bay Hiro | Jul 27, 2008

Click on an option to vote

496

votes

  • 50-100 miles?
  • 100-300 miles?
  • 500+ miles?

Los Angeles Jobs

Topix Extras